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Quaternary prevention – an (increasingly) important theme in family medicine   
“Prevention is better than cure”. This principle is undisputed. New knowledge points to the fact that prevention 
can also do harm. Under the concept “quaternary prevention” efforts are currently focused on finding the right 
measure of preventive care, true to the old medical tenet “primum non nocere”. 
The Editors of PrimaryCare have pleasure in joining this trailblazing new discussion via the article of Thomas 
Kuehlein et al., which in its present form is based on Marc Jamoulle’s workshop “About quaternary prevention” 
at the European Wonca Congress 2009 in Basel. We publish it unabridged.  
The contribution appeared in several languages, and can be found in English, Spanish, Italian, Portuguese and 
Croatian at www.primary-care.ch. 
For further information on quaternary care please consult the website http://docpatient.net/mj/P4_citations.htm. 
 
Abstract 
Quaternary prevention is the prevention of unnecessary medicine or the prevention of 
overmedicalisation. The principle of “primum non nocere” is central to the whole of medicine. The task 
to avoid excess medical interventions is particularly mandatory in the field of general practice. We 
report on a workshop on this topic held at the 15th Wonca Europe Conference in Basel, in September 
2009. In a world of growing obsessions with health matters and rising possibilities of “doing 
something”, there is a need for someone to give advice about the appropriateness of medical 
procedures. Mainly in the name of prevention, there has been an explosion of new disease labels and 
health care measures that warrant a rethinking of the objectives and underlying philosophy of primary 
care. Especially in an area of high grades of uncertainty and low prevalence of severe diseases, the 
most difficult thing for the physician is the decision not to pursue further action and to protect our 
patients from unnecessary medicine. This decision can firmly be grounded on probabilities arising from 
clinical studies on the one side and the individual life stories and values of our patients on the other. 
We propose to make quaternary prevention more explicitly the task of the general practitioner. 
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T.M., 62 years old and up to now a healthy man, comes to see his general practitioner. In a journal 
distributed by the local pharmacy he has learned about the rising number of men his age, diagnosed 
with cancer of the prostate gland. He asks for screening for prostate cancer with PSA-testing. As the 
test is not covered by his health care insurance, he is willing to accept that he will have to pay for it 
himself. He does not have any problem with voiding or his sexual life. There is no history of prostate 
cancer in his family. He says: “You know, I was always in good health but I feel I am coming to a 
certain age now and my wife said that I should start to do something to stay healthy”. 
What should the advice of his doctor be? 
 
The workshop in Basel 
We are reporting on a workshop held at the 15th Wonca Europe Conference in September 2009 in 
Basel. The title of the workshop was “Quaternary Prevention” (QP). To make it clear in the beginning, 
QP is the prevention of overmedicalisation or the prevention of unnecessary medicine. One of the 
fundamental principles of medicine is “primum non nocere”. The aim, therefore, is to detect patients at 
risk for excess medical procedures that will probably do them more harm than good and to offer them 
acceptable alternatives. 
 Workshops are places where not only things and ideas are presented, but where they are also 
further developed by the input from the participants. There were three presentations on the topic, 
followed by a vivid discussion. In this article, we use the input from the participants to further develop 
our ideas concerning QP.  
 
Primary, secondary, tertiary and quaternary prevention – patient’s illness and doctor’s disease 
The levels of prevention have been defined and used differently [1]. Even the term QP has been used 
in different ways [2]. As general practitioners, we refer here to the concept of QP as first published by 
one of the authors Marc Jamoulle (MJ) in 1986 [3]. In 1999, it was accepted as a concept by the 
Wonca International Classification Committee and published in 2003 in the Wonca Dictionary of 
General/Family Practice [4].  
Leavell and Clark, in 1958, defined the different levels of primary and secondary prevention as health 
measures before and after the disease in question comes into existence. Secondary prevention was 
confined to early disease stages, for example disease detected by screening. Tertiary prevention was 
related to avoiding complications of already clinically manifested diseases and was used for 
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rehabilitation measures [5]. This and similar views have always been driven by doctor centred 
approaches to health care.  
MJ’s concept introduces a new strategy, combining patient and doctor’s views and elaborating on a 
prevention concept based on this relationship. His new way of dealing with the prevention concept 
breaks away from the former chronological way. It can now be seen as the crossing between the 
patient’s mind (illness or health) versus the doctor’s appraisal (disease or no disease). When using 
the terms illness and disease, we here refer to Arthur Kleinman and his famous book ‘The Illness 
Narratives – Suffering, Healing and the Human Condition’ [6]. Kleinman made the distinction between 
illness as “the principal difficulties that symptoms and disability create in our lives” on the one hand. 
Disease in contrast was defined as “what the practitioner creates in the recasting of illness in terms of 
theories of disorder. Disease is what practitioners have been trained to see through the theoretical 
lenses of their particular form of practice. That is to say, the practitioner reconfigures the patient‘s and 
family‘s illness problems as narrow technical issue”.  
The feeling of being ill does not necessarily meet the doctor’s judgment that there is a disease 
present. However, there are more and more disease labels attached to patients who feel perfectly 
well. In fact the most common so called “chronic conditions”, such as hypertension, diabetes, 
osteoporosis and many others, are diseases without illness. As Charles Rosenberg once put it: 
“…contemporary medicine and bureaucracy have constructed disease entities as socially real actors 
through laboratory tests, pathology-defining thresholds, statistically derived risk factors, and other 
artefacts of the seemingly value-free biomedical enterprise.” [7] 
Figure one gives an idea of what this new approach of classifying prevention is about. 
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As a further development to the original table (http://docpatient.net/mj/P4_citations.htm) we have put 
disease into the dichotomy and mutual exclusiveness of absent and present. Illness in contrast has a 
continuum between absence and presence. 
  
Primary, secondary and tertiary prevention are well known tasks of the physician.  
In primary prevention there is neither illness, nor disease. Strictly speaking, the patient is not a 
patient. The prevention measures would be to talk about a healthy lifestyle and to take vaccinations 
for example.  
In secondary prevention there are conditions present in the form of disease labels. Most of them will 
be risk factors and as such, it is debatable whether they should be disease entities in their own right. 
Another example would be early disease stages detected by screening, such as early prostate 
cancer. The now called patient feels perfectly well, except for being threatened by the knowledge of a 
disease. Disease labels such as hypertension, diabetes mellitus type II, hypercholesterolemia or 
osteoporosis are defined by arbitrary cut-offs in a continuum of measurement readings. The aim of 
secondary prevention is to reduce the risk of certain endpoints of these conditions, such as 
myocardial infarction, stroke or fractures. Thus, strictly speaking, the treatment for hypertension for 
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example is prevention not treatment, as there is no illness present. The concept of risk factors is quite 
new, but has gained wide popularity within a fairly short time [8]. Most of the patients with risk factors 
will, in fact, never develop the complications they are at risk for. Nevertheless it is possible to define 
these patients as having chronic diseases or, if they have more than one of them, even multimorbid. 
We should not frighten our patients by making them aware that life itself is a risk factor for death, 
when in fact it is a predisposition for death (Fig 2). 
 









Much has been learned about the importance of risk factors being relative. One example is that we 
should not treat hypercholesterolemia as a measure of secondary prevention by itself, if the overall 
risk for cardiovascular complications is low. However, we might try to protect patients with relatively 
low cholesterol readings by prescriptions of a statins if their overall risk is high. Another form of 
secondary prevention would be cases of early disease stages found by screening. The majority of men 
over 80 will have prostate cancer [9]. Only few of them will die from it [10]. 
Tertiary prevention is the only point where illness and disease coincide. An example would be a 
patient having had a myocardial infarction. These patients not only have risk factors for myocardial 
infarction, but, for whatever reason, they have developed one. They now have the highest risk to 
risk 
Helping the patient to manage uncertainty 
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suffer a second one in the future. We should clearly try to prevent this with all the measures we have, 
provided this makes sense according to the life circumstances and will of the patient.  
In QP we have the problem of illness without disease. While the patient experiences illness and 
deserves a disease label, doctors, as newly proposed, would label a majority of these illnesses as 
MUS (medically unexplained symptoms) [11]. Many terms and underlying concepts have been used 
for these illnesses in medical history [12]. One is psychosomatic illness. Despite containing the word 
somatic, the concept sees the cause clearly on the psychic side, with the effect being only felt 
somatically. However, there are efforts to construct somatic disease labels, such as fibromyalgia, 
which is highly welcomed by most patients who feel relieved from the perceived blame of a 
psychiatric disorder. All these symptoms and illnesses widely open up the doors for endless 
diagnostic procedures. Most of them will have normal results, but many will have borderline or false 
positive results. The consequences are endless further diagnostic tests and prescriptions of never 
proven therapies with well known side-effects. The problem is also that, as shown in figure 1, there is 
a continuum between health and illness in contrast to a dichotomy between not having a disease and 
having a disease. Most people in fact do have symptoms at a given point in time [13]. Most of them 
will not consult a doctor in spite of that, but they can be made to do so. We might call these patients 
the “worried well”. In fact the media, the pharmaceutical industry, politicians and the medical 
professions in a weird mixture of best intentions and economic profit have the potential to create 
doubt and worries about even the most robust health of the people [14,15]. As one of the authors 
Juan Gérvas (JG) once put it in a presentation: “I am going to prove, that you all are dead”. Next he 
told us about a new guideline for heart failure [16]. It defines four stages of heart failure. Stage A is for 
people without structural heart disease or symptoms of heart failure, but who are “at risk” for it. At the 
end of his presentation on heart failure, he came back to his statement from the beginning: “Now you 
can see that you are all dead – but fortunately only stage A!” There is a lot of truth in this joking. 
Stage B of heart failure is for people with structural heart disease, but without signs or symptoms with 
heart failure. Are the people labelled as having heart failure stage A and B really patients? Is it really 
the worry for our patients that drives us? Or is it the cynical broadening of the narrow spectrum of 
patients by doctors who are more and more specialised and by this rising specialisation have less 
and less patients? Or is it the seemingly moral free activity of pharmaceutical companies in search of 
new consumers for their products? Probably it is neither only this, nor only that. It is a danger we are 
all in. The consequences of this danger will be felt mainly by our patients or by the people whom we, 
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more or less intentionally, make our patients. This is what we should keep in mind with every action 
we take, and this is why we think it is important to have a name for this task: QP.  
One reaction of our patients, followed by many of our colleagues in general practice, in face of the 
often frightening technical character of modern medicine is the romantic retreat to so called 
alternative or complementary forms of medicine. We believe that there is no alternative to good 
medicine founded, as far as possible, on robust science on the one hand and respectful 
understanding of the fears and wishes of our patients on the other. If modern medicine is missing 
empathy and human understanding beyond measurable and technically manageable things, this is a 
deficit. If there is a deficit, we should call it that and not try to add what is missing as a seeming 
alternative or complement.  
 
How to promote QP 
What then can we do to promote QP? In the discussion at the workshop, there was a colleague who 
argued that little can be done by a sole general practitioner faced with the overwhelming power of so 
many profiteers of the contrary. However, we are not alone. UEMO, the professional representation of 
general practitioners/ family physicians in Europe, supports the idea of QP [17]. We think that there is 
a lot that can be done. The first would be to further promote the concept of QP and thus to keep it in 
mind ourselves as one of our genuine tasks and to discuss it with colleagues. We believe that QP is 
so inherent in the world of the generalist, that most of us will have practiced it already in one way or 
another, without explicitly calling it like that. What we will need to follow further will be the concept of 
strong weapons on the one hand and allies on the other. The most difficult thing for doctors and their 
patients is the decision not to pursue further diagnostics and therapy [18]. The human mind seems to 
be more open to action, even if it turns out to be useless or even harmful, than to no action or a ‘wait 
and see’ approach. This can turn into absurdities such as women continuing to have Pap-smears in 
69% of cases after having had a complete hysterectomy in the US [19]. In these cases it seems 
relatively easy to be convinced of QP. However, what can be done in so many other conditions with 
floating boundaries and a huge overlap of benefit and harm? A meaningful benefit at the population 
level does not automatically translate into a meaningful benefit at the level of the individual patient. 
This probably holds true for many cases of secondary prevention. Geoffrey Rose distinguished the 
causes of incidences and the causes of cases in his famous article on sick individuals and sick 
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populations [20]. Preventive medicine was readily misunderstood by so many, such as to apply the 
high-risk strategy for individual patients to bigger and bigger parts of the whole population [21].  
One of the strongest risk factors for many diseases and for the still inevitable outcome, death, is age. 
Yet, there is no clear boundary of when it is futile to try to prevent one disease, when the probability 
to die from so many other diseases strongly related to age becomes overwhelming. Few people 
would still discuss the usefulness of statins for a patient with severe dementia and a high grade 
decubital ulcer. Polypharmacy and thus patient safety is a major concern in the care of the elderly. 
The question which preventive medication can be stopped and when is the task of the general 
practitioner together with the patient or maybe his or her relatives. QP, thus, can also be the 
prevention of unnecessary prevention.  
One of the strongest methods to avoid unnecessary medical processes is Evidence based Medicine 
(EbM) in the sense that it was originally developed by David Sackett and colleagues [22]. The 
knowledge of the probabilities of effect sizes of benefit and harm from clinical studies, can provide us 
with confidence about the possibility to leave out many diagnostics and medications in concordance 
with our patients. If we keep stuck in the dichotomy of “works/ works not”, we will not be able to leave 
out a given medication.  
However, it is not only about therapy. Chris del Mar and colleagues from Australia mentioned in a 
highly recommendable book about clinical thinking [23], a new and dangerous syndrome called 
VOMIT. VOMIT is an acronym for “Victim Of Modern Imaging Technology”. It is far easier to 
recommend any useless diagnostic test “for safety reasons” than to discard it. The difficulty lies in the 
possibility to be wrong when seemingly ruling out any disease as the cause of the patient’s illness. 
Additionally how do we tell the patient that we did not find anything as an explanation and as a 
consequence will not be able to help? It is important not to leave the patients alone with their illness, 
simply because we have no disease label for the problem. The positive predictive values of diagnostic 
test results in areas of low prevalence for the most severe diseases are fairly low, even if their 
sensitivities are high [24]. If we as general practitioners had been taught more about the 
consequences of Bayes’ theorem for the validity of positive test results in our setting, we probably 
would be more restrictive in ordering tests in many cases. The problem has been that our most 
specialised teachers did not know about it. Knowledge, not mistrust, is the best means for QP. 
Another lever of QP is the person or life story of the individual patient in front of us. Many medical 
processes won’t make any sense or are even absurd in face of the life circumstances of some of our 
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patients. This approach has been named “Narrative based Medicine” [25]. It automatically leads to 
the strongest means we have to effectuate QP: communication and the trust of our patients, that we 
hopefully have earned over a long period of time.  
However, before we try to convince others of the importance of QP, we should easily begin with it in 
our own practices. We can begin, for example, by ordering less useless laboratory tests when doing 
check-ups, less X-rays in cases of uncomplicated back pain or less prescriptions of antibiotics in 
cases of acute bronchitis or rhinosinusitis, where they are clearly of little or no benefit. There is 
enough evidence and enough guidelines to protect us from malpractice claims in the rare cases of 
complications. The threat of malpractice sues is one of the major drivers of useless medical 
procedures. We hope that our judges “will be kinder on [our] sins of commission than on [our] sins of 
omission” [26]. There is no sense in treating many patients with possibly harmful medications, “for 
safety reasons” to possibly prevent rare complications of a very few. Guidelines from our own national 
colleges of general practice are mostly seen as proscriptive and are therefore rejected [27]. They 
should not be seen as a prohibiting “you must not”, but should be seen as a protecting “you need 
not”. 
 
A patient asking for testing PSA 
Let us come back to our patient from the beginning. What will we tell him? We might tell him that it is 
true that there are more and more people of his age diagnosed with prostate cancer, but that this is 
only a logical consequence of more screening activity. The rate of death from prostate cancer has 
been declining in countries with and without screening [28]. We might tell him that this year two big 
trials have been published of which one showed no  effect of prostate cancer screening concerning 
mortality [29], and the other showed a minimal effect [30]. We could give the patient the URLs of 
some websites giving reliable information about the topic or an information leaflet. As male 
physicians, we could tell him how we would decide for ourselves. We should always be fair and open 
to the possibility that the patient wants screening to be done in spite of our objections against it. QP 
can only be accomplished in concordance with our patients and never against them. The patient will 
usually be our strongest ally for QP if he or she sees that we are not arguing out of self interest or 
ideology. The aim should not be a crusade against medical technology and progress but a 




QP is the prevention of unnecessary medical interventions and as such a foundation block of 
medicine (primum non nocere). The strongest means to accomplish this is to listen better to our 
patients. This is what has been termed Narrative based Medicine, which means to adapt the 
medically possible to the individual needs and wants. What we need is a strong and sustainable 
relationship with our patients and their trust in our honesty and specific knowledge. The other 
important means is called Evidence based Medicine. The knowledge of the probable predictive 
values of diagnostic tests and the probabilities of effect sizes of benefit and harm of therapy and 
preventive measures give us the opportunity to leave out many useless procedures. We think that QP 
is a genuine task of the general practitioner. It should be more openly discussed. There should be 
more research and teaching about it. 
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